"We started entering the personalized therapy era for early stage patients,"Pennell, who did not take part in the trials, and noted that"we should firmly close the door on one-size-fits-all treatment for people with non- small cell lung cancer."
Osimertinib is already authorized in dozens of countries for various indications, and has already been given to some 700,000 people,Its approval in the United States for early stages in 2020 was based on previous data that showed an improvement in patient disease-free survival, that is, the time a patient lives without a recurrence of cancer.
But not all doctors have adopted the treatment, and many were waiting for the data on overall survival that was presented on Sunday,He stressed the need to screen patients to find out if they have the EGFR mutation. Otherwise, heOsimertinib, which targets the receptor, causes side effects that include severe fatigue, skin rashes, or diarrhea.
Law Law Latest News, Law Law Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: TucsonStar - 🏆 339. / 59 Read more »
Source: mercnews - 🏆 88. / 68 Read more »